ACRV - CIK 0001781174
The table below shows Acrivon Therapeutics, Inc.'s income statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q1 2026 | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - |
| Cost of revenue | - | - | - | - | - | - |
| Gross profit | - | - | - | - | - | - |
| R&D | $15.17M | $13.65M | $16.18M | $15.41M | $18.86M | $15.03M |
| SG&A |
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| $4.74M |
| $6.04M |
| $6.47M |
| $6.25M |
| $6.28M |
| $6.41M |
| Operating income | -$19.90M | -$19.69M | -$22.65M | -$21.66M | -$25.14M | -$21.44M |
| Income tax | - | - | - | - | - | - |
| Net income | -$19.04M | -$18.23M | -$21.01M | -$19.68M | -$22.44M | -$18.80M |
| EPS (diluted) | -$0.49 | -$0.47 | -$0.55 | -$0.51 | -$0.59 | -$0.52 |